You just read:

New Phase 3 Monotherapy Study of Sirukumab Versus Humira® and Sirukumab Data in an Anti-TNF Refractory Population Reported in the Treatment of Moderately to Severely Active Rheumatoid Arthritis

News provided by

Janssen Research & Development, LLC

Nov 16, 2016, 11:00 ET